A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)
A phase 3 trial of Izalontamab brengitecan, Capecitabine, Gemcitabine in nasopharyngeal carcinoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
Overview
A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) is a phase 3 interventional study registered as NCT06118333 by Sichuan Baili Pharmaceutical Co., Ltd., with 386 participants enrolled, started 2023-12-04 and due to reach its primary completion in 2026-11. Interventions recorded: BL-B01D1, capecitabine, gemcitabine, docetaxel. Conditions listed: Nasopharyngeal Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other
Shares Izalontamab brengitecan, Nasopharyngeal carcinoma, SystImmune / Sichuan Biokin.
- TrialA Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Docetaxel.
- TrialA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and
Shares Izalontamab brengitecan, Nasopharyngeal carcinoma, SystImmune / Sichuan Biokin.
- TrialA Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
Shares SystImmune / Sichuan Biokin, Capecitabine, Gemcitabine.
- TrialA Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin.
- TrialA Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin.
- TrialA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin.
- TrialA Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANK
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin.